The family cat curled up on a sofa may seem an unlikely ally in the fight against human cancer.

But a major genomic study suggests domestic cats could become surprisingly valuable partners in understanding—and eventually treating—cancer in both species.

Researchers analyzed tumours from 493 pet cats, comparing each tumour with healthy tissue from the same animal. Across 13 different types of feline cancer, they searched approximately 1,000 genes already associated with cancer in humans.

What they discovered was striking.

Many of the same genetic systems that malfunction in human cancer also break down in cats.

The clearest example was TP53, one of the most important tumour-suppressor genes in biology.

TP53 was mutated in:

33% of the feline tumours.

In large human pan-cancer datasets, the comparable figure is approximately:

34%.

That extraordinary similarity does not mean cat cancer and human cancer are identical.

They are not.

But it suggests that cancer repeatedly exploits some of the same biological weaknesses in two mammalian species that have shared homes and environments for thousands of years.

The research, published in Science in February 2026 under the title The oncogenome of the domestic cat, represents the first large-scale genetic survey across multiple types of feline cancer.

And its implications extend far beyond veterinary medicine.

Researchers argue that naturally occurring cancers in pet cats could provide a powerful bridge between veterinary and human oncology—a philosophy often called:

One Medicine.

The idea is simple:

What doctors learn about cancer in humans may help cats.

And what veterinarians learn from treating naturally occurring cancer in cats may eventually help humans too.

Why Scientists Sequenced Nearly 500 Cat Tumours

Cancer is a major cause of disease and death in domestic cats, yet compared with humans—and even dogs—the genetics driving feline cancer has historically remained poorly understood.

Modern human oncology increasingly depends on tumour genomics.

Doctors can sequence cancers to identify mutations that:

• drive uncontrolled cell growth;
• disable tumour suppressors;
• activate growth signalling;
• influence prognosis;
• predict whether particular targeted drugs may work.

Veterinary oncology has begun moving in the same direction.

But researchers first need a detailed map of the mutations occurring in different animal cancers.

That map barely existed for cats.

The international research team therefore assembled tissue collected from pet cats in five countries.

Importantly, these were not laboratory animals deliberately given cancer.

The samples came from animals that had naturally developed tumours and whose veterinarians had already collected tissue for diagnostic purposes.

For each cat, researchers compared:

tumour DNA

with:

normal DNA from the same individual.

That allowed them to distinguish mutations that arose in the tumour from genetic variants the animal had inherited.

The Study Examined 493 Tumour-Normal Pairs

In total, scientists performed targeted DNA sequencing on:

493 feline tumour-normal pairs

representing:

13 cancer types.

Rather than sequencing every gene in the genome, they focused particularly on feline equivalents of roughly:

1,000 genes known to be associated with human cancer.

The aim was not simply to catalogue mutations.

Researchers wanted to identify driver genes.

These are mutations that actively contribute to cancer development rather than genetic changes that merely accumulate as the tumour grows.

The study ultimately identified:

31 cancer driver genes.

It also examined:

• copy-number alterations;
• mutational signatures;
• viral sequences;
• inherited cancer-predisposing variants.

The result is effectively the first broad genetic atlas of cancer in the domestic cat.

TP53 Was the Most Frequently Mutated Gene

Of all the genes studied, TP53 stood out.

TP53 encodes the p53 protein, one of the body's most important protections against cancer.

Its job includes responding when cells experience serious DNA damage.

Depending on the situation, p53 can:

• pause cell division;
• activate DNA repair;
• push severely damaged cells toward programmed death.

Because of this role, TP53 is often described as a tumour-suppressor gene.

When TP53 itself becomes damaged, cells carrying dangerous mutations can continue dividing.

That is why TP53 alterations occur so frequently across human cancer.

In the feline study, researchers found TP53 mutations in:

33% of all tumours analyzed.

Human pan-cancer studies have reported TP53 mutations in approximately:

34% of tumours.

The near match immediately attracted attention.

Cancer in cats and cancer in humans may develop in different organs and under different circumstances, but some of the fundamental genetic vulnerabilities appear remarkably conserved.

TP53 Was Not the Only Shared Cancer Gene

Researchers also identified recurrent alterations involving genes familiar to human oncologists.

Among the most common copy-number changes in feline cancers were:

• loss of PTEN;
• loss of FAS;
• gain of MYC.

Each occurred in approximately 20% of the cat tumours in the study.

These genes participate in cellular systems controlling:

• proliferation;
• survival;
• programmed cell death;
• growth signalling.

Similar pathways are frequently disrupted in human cancers.

This cross-species overlap is scientifically valuable because it helps researchers identify mutations that are likely to be genuinely important.

If the same gene repeatedly becomes altered in comparable cancers across different mammals, that strengthens the case that the change is biologically meaningful rather than simply genetic noise.

But Cat Cancer Is Not Simply Human Cancer in a Smaller Patient

The similarities are exciting.

The differences may be equally informative.

One striking example involved the RAS family of genes.

Activating RAS mutations occur in roughly a quarter of human cancers and are especially important in certain pancreatic, colorectal and lung cancers.

Yet in the feline study, RAS did not emerge as a driver in any of the tumour types examined, consistent with earlier observations that hotspot RAS mutations appear relatively uncommon in cats.

That contrast matters.

Comparative oncology is useful not only when two species are similar.

Differences can reveal:

• which pathways are essential in one species but not another;
• how environmental pressures shape cancer;
• why certain tumour types respond differently;
• which animal cancers are appropriate models for specific human diseases.

A good biological model does not need to reproduce everything.

It needs to reproduce the feature scientists are trying to understand.

Feline Mammary Cancer Was Especially Interesting

One of the strongest comparisons involved feline mammary carcinoma.

Mammary tumours are among the important cancers affecting female cats and are often aggressive.

Researchers identified seven driver genes associated with feline mammary carcinoma.

The most common was:

FBXW7.

More than:

50% of feline mammary tumours

contained alterations involving this gene.

FBXW7 plays an important role in controlling the destruction of proteins involved in cell growth.

When it stops functioning properly, proteins that should be removed can accumulate and promote cancer.

Human breast cancers can also contain FBXW7 alterations, where they have been associated with poorer outcomes.

That makes feline mammary cancer particularly interesting for comparative research.

PIK3CA Was Altered in Nearly Half of Feline Mammary Tumours

Another familiar cancer gene appeared frequently:

PIK3CA.

Researchers found PIK3CA alterations in approximately:

47% of the feline mammary carcinomas examined.

PIK3CA is also one of the major driver genes in human breast cancer.

Its protein forms part of the PI3K signalling pathway, which influences:

• cell growth;
• metabolism;
• survival.

Targeted PI3K inhibitors are already used for selected human cancers carrying relevant pathway alterations.

The fact that comparable mutations arise naturally in cats raises a fascinating possibility:

Some targeted treatment concepts developed in humans might eventually benefit feline patients with matching molecular abnormalities.

Researchers Already Tested Drug Responses in Cat Cancer Tissue

The study went beyond sequencing alone.

Researchers also grew feline mammary carcinoma tissue in culture and tested how tumours with particular genetic alterations responded to drugs.

They reported that some chemotherapy treatments were more effective against feline mammary cancer cells carrying FBXW7 alterations.

This finding is preliminary.

It was performed using tumour tissue in laboratory conditions.

It was not a clinical trial in living cats.

That distinction is critical.

Cancer cells responding to a treatment in a dish does not guarantee that the same treatment will be safe or effective in an animal.

Researchers will need further:

• laboratory studies;
• pharmacology;
• veterinary trials;
• safety testing.

Still, the experiment demonstrates how genomic information can start becoming clinically useful.

Instead of treating all feline mammary cancers as one disease, veterinarians may eventually be able to classify them by their molecular drivers.

That is the foundation of precision oncology.

Precision Medicine Has Transformed Human Cancer Care

For much of medical history, cancers were classified primarily by where they originated.

Breast cancer.

Lung cancer.

Colon cancer.

Bone cancer.

Genomic medicine has complicated that picture.

Two tumours arising in the same organ can behave very differently because they are driven by different mutations.

Conversely, cancers arising in different organs can sometimes depend on the same molecular pathway.

That insight led to targeted therapies aimed at specific abnormalities.

The new feline oncogenome could eventually allow veterinarians to move in the same direction.

A cat's tumour might one day be characterized not simply as “mammary carcinoma,” but as a mammary carcinoma carrying a particular actionable mutation.

Senior author Louise van der Weyden described the work as an important step toward bringing precision feline oncology closer to the options already available in human and canine medicine.

Why Cats May Be Especially Useful Cancer Models

Mice have been indispensable to biomedical research.

But laboratory mice and domestic cats represent very different biological circumstances.

Experimental mice:

• are usually genetically controlled;
• live in highly standardized environments;
• often develop cancers that are deliberately induced or genetically engineered;
• have relatively short lifespans.

Pet cats develop cancer naturally.

They also live in human households.

They may breathe much of the same air as their owners.

They can encounter some of the same:

• household chemicals;
• air pollutants;
• tobacco smoke;
• environmental contaminants.

Researchers therefore argue that naturally occurring feline cancers may sometimes capture combinations of genetics, aging and environmental exposure that laboratory systems cannot fully reproduce.

That does not make cats universally “better than mice.”

Different models answer different questions.

But cats may offer a useful additional layer between laboratory experiments and human trials.

Cats Also Develop Cancer Spontaneously

This is another important advantage.

A laboratory tumour model is usually designed around a scientific question.

Researchers may insert a cancer-causing mutation, transplant tumour cells or expose animals to a carcinogen.

That level of experimental control is useful.

But human cancers do not usually arise that way.

They emerge spontaneously after years of interacting factors such as:

• inherited susceptibility;
• random mutations;
• aging;
• environment;
• immune function.

Pet cats experience that kind of biological complexity too.

Their cancers emerge naturally over the course of life.

That similarity is one reason comparative oncology increasingly focuses on companion animals.

Sharing a Home Does Not Mean Cats and Owners Develop the Same Cancer

The environmental argument needs careful interpretation.

A cat living with a person may share certain exposures.

But that does not mean a cat's cancer was caused by exactly the same thing that caused a human household member's cancer.

Cancer is almost always multifactorial.

Even when two individuals encounter the same carcinogen, their:

• genetics;
• metabolism;
• age;
• immune systems;
• dose;
• duration of exposure

may differ significantly.

The importance of cats as models comes from the opportunity to investigate how naturally occurring cancer interacts with real-world environments—not from an assumption that pets and owners develop identical tumours for identical reasons.

What Is “One Medicine”?

The philosophy underlying the study is often called:

One Medicine.

It treats human and veterinary medicine as connected rather than completely separate disciplines.

Cancer provides an especially powerful example.

Many of the genes controlling:

• DNA repair;
• cell division;
• immune surveillance;
• apoptosis;
• growth signalling

are evolutionarily conserved across mammals.

A mutation damaging one of those pathways can therefore produce similar consequences in different species.

The Sanger research team describes One Medicine as a two-way exchange of knowledge between human and veterinary oncology.

The direction of benefit should work both ways.

Human medicine may provide:

• targeted drugs;
• biomarkers;
• sequencing methods;
• diagnostic strategies

that could improve cancer treatment in cats.

Meanwhile, naturally occurring feline cancer could help scientists study:

• treatment response;
• resistance;
• environmental influences;
• disease progression

in a biologically realistic setting.

This Is Not About Giving Experimental Human Drugs to Pets Without Safeguards

The phrase “test human cancer drugs in cats” can sound troubling if stripped of context.

Researchers are not proposing that companion animals simply replace laboratory animals in uncontrolled experiments.

Veterinary clinical trials are governed by:

• ethical review;
• owner consent;
• animal-welfare standards;
• veterinary oversight.

The objective is to investigate treatments that might plausibly benefit the cat receiving them, while also generating knowledge that may help other animals and potentially people.

That is an important ethical foundation of comparative oncology.

The cat is a patient, not merely a research instrument.

The Same Mutation Could Point to the Same Therapeutic Vulnerability

Imagine a human tumour and a feline tumour that both depend heavily on the same altered signalling pathway.

A drug targeting that pathway already exists.

Researchers could potentially ask:

Does the drug work in feline cancer?

What resistance mechanisms emerge?

How does the tumour change over time?

If the cat benefits and scientists learn more about the mutation, both veterinary and human medicine gain useful information.

Conversely, a treatment discovered through feline research might later reveal a promising target worth investigating in humans.

This two-directional flow is precisely what researchers mean by One Medicine.

Cats Could Help Researchers Study Treatment Resistance

One of cancer medicine's greatest challenges is not simply destroying tumours.

It is preventing them from returning.

Tumours evolve.

A treatment may initially eliminate most cancer cells.

But a small population carrying resistance mechanisms survives.

Those cells reproduce.

The cancer returns.

Because pet cats develop naturally heterogeneous tumours, researchers may eventually be able to study these evolutionary processes in ways complementary to laboratory models.

Serial tumour sequencing could potentially reveal:

• which mutations disappear after treatment;
• which survive;
• which new mutations arise;
• which pathways allow resistance.

That kind of information can be extremely valuable for understanding cancer evolution.

Why Domestic Cats Have Been Underused in Cancer Research

Dogs have traditionally attracted much more attention in comparative oncology.

There are several reasons.

Certain canine cancers closely resemble human disease.

Dogs are often larger, making some procedures easier.

Veterinary cancer clinical-trial networks have also been developed more extensively for dogs.

Cats have lagged behind.

The new genomic atlas begins addressing one of the biggest obstacles:

scientists previously lacked a detailed reference showing which mutations actually occur across feline cancers.

The Science study effectively turns the feline oncogenome from what researchers described as a “black box” into a searchable genetic resource.

The Data Have Been Made Available for Future Researchers

Another important part of the project is that the genetic information is intended as a community resource.

Rather than treating the sequencing effort as an isolated experiment, researchers created a dataset that other scientists can use to:

• compare tumour types;
• investigate specific genes;
• design clinical studies;
• search for therapeutic targets.

This matters because the first cancer atlas rarely provides all the answers.

Its greater value may be enabling hundreds of later studies.

The Study Also Found Cancer-Associated Viral Sequences

Cancer is not driven exclusively by spontaneous genetic mutation.

Some viruses can contribute to tumour development.

The feline cancer project detected viral sequences in specific tumour types, including papillomaviruses previously associated with feline skin cancers.

This illustrates how genomic sequencing can uncover several layers of cancer biology simultaneously.

Researchers can look for:

• inherited variants;
• tumour mutations;
• copy-number changes;
• mutational signatures;
• infectious agents.

The resulting picture is much richer than simply asking whether one gene is mutated.

Inherited Cancer Risk Can Also Be Investigated

Because scientists sequenced normal tissue alongside tumours, they could also identify germline variants—genetic differences an animal was born with rather than mutations arising only in cancer cells.

That creates possibilities for future work on inherited cancer susceptibility in cats.

Different breeds have gone through varying degrees of selective breeding and population bottlenecks.

Those genetic histories could make certain inherited disease variants easier to track.

In principle, studying feline predisposition genes might eventually benefit:

• breeding programs;
• veterinary screening;
• comparative cancer genetics.

Are Feline Mammary Tumours the Same as Human Breast Cancer?

No.

But they share biologically meaningful features.

Both arise from mammary tissue.

Both can be aggressive.

And the new genomic study identified overlapping cancer-driving pathways, including genes such as PIK3CA and FBXW7.

That makes feline mammary carcinoma an interesting comparative model.

But researchers must still account for major differences involving:

• hormone biology;
• reproductive history;
• tumour subtype;
• immune environment;
• species-specific genetics.

The correct scientific conclusion is not:

“Cat breast cancer is human breast cancer.”

It is:

“Some feline mammary cancers share genetic mechanisms with human breast cancers strongly enough to justify comparative investigation.”

Could This Research Lead to Better Treatments for Cats First?

Very possibly.

The most immediate beneficiaries may be feline patients themselves.

Human oncology has entered an era in which molecular testing can guide treatment for many cancers.

Veterinary medicine has fewer targeted options.

The new genomic atlas identifies mutations that could potentially be actionable with:

• existing human medicines;
• veterinary drugs;
• newly developed targeted therapies.

That does not mean veterinarians can immediately begin prescribing human targeted treatments.

Dosage, metabolism, toxicity and effectiveness must be studied specifically in cats.

But researchers now know much more precisely where to look.

Could Human Cancer Patients Benefit Too?

Potentially—but this would take time.

No new human cancer treatment was proven by this study.

No human therapy should change because TP53 mutations occurred at nearly identical frequencies in cats and humans.

Instead, the study establishes a foundation.

Future research could use cats with spontaneous cancers to investigate therapeutic questions that are difficult to answer completely with cell cultures or laboratory models.

If a therapy succeeds—or fails—in cats carrying the same tumour driver as human patients, that evidence could help researchers decide which approaches deserve further human study.

It would complement human trials.

It would not replace them.

The 33% Versus 34% Statistic Is Striking—but It Should Not Be Overinterpreted

The near-perfect match between feline and human TP53 mutation frequencies is an excellent illustration of shared cancer biology.

But it does not mean cats and humans have a 99% identical cancer profile.

The percentages come from pan-cancer datasets containing different mixtures of tumour types.

A change in which cancers were sampled could alter the overall numbers.

What matters scientifically is that TP53 emerges as a major driver in both species.

The similarity in frequency reinforces that observation.

It should not be interpreted as proving every tumour type behaves identically.

Why TP53 Keeps Appearing Across Species

TP53's importance is not accidental.

Multicellular organisms face a fundamental challenge.

Their cells must divide when needed—but stop dividing when damaged.

Cancer develops when those restraints fail.

p53 lies near the center of several systems designed to prevent defective cells from reproducing.

Because mammalian cells share much of this machinery, damaging TP53 can provide a powerful evolutionary advantage to tumour cells across species.

That is why finding the same gene repeatedly altered in cats and humans is so compelling.

Cancer has discovered the same vulnerable control switch twice.

The Study Shows Both the Power and Limits of Comparative Oncology

Comparing species can reveal patterns impossible to see from one species alone.

If the same alteration repeatedly drives similar cancers in:

humans,

cats,

dogs,

then researchers gain stronger evidence that the gene is central to tumour biology.

But comparison also exposes differences.

The absence of common RAS drivers in this feline dataset, despite their enormous importance in humans, is one example.

Those differences keep scientists from treating pets as miniature humans.

They also generate new questions.

Why does one cancer pathway dominate in humans but not cats?

What biological mechanism protects one species?

Could understanding that difference reveal a therapeutic opportunity?

Sometimes the mismatch may be more informative than the similarity.

The Research Also Changes How We Think About Pet Animals

Dogs and cats have traditionally entered biomedical science either as veterinary patients or as experimental organisms.

Comparative oncology introduces a third relationship.

They can become partners in naturally occurring disease research.

A cat diagnosed with cancer is already experiencing a disease that needs treatment.

Studying that cancer genomically can potentially improve:

• the animal's diagnosis;
• treatment selection;
• veterinary knowledge;
• human cancer biology.

When designed ethically, these goals do not necessarily conflict.

They can reinforce one another.

The Source Date Needs One Small Clarification

The research itself was not first published in September 2026.

The peer-reviewed Science paper appeared on February 19, 2026.

The ScienceDaily story bringing renewed attention to the work was published on September 26, 2026, based on material from the University of Guelph.

That distinction matters when describing a scientific breakthrough.

The discovery dates to the February Science publication, while the September coverage helped bring it back into public attention.

The Bottom Line

An international research team has produced the first large-scale genetic atlas of cancer in domestic cats.

The scientists analyzed:

493 tumour-normal tissue pairs

from:

13 types of feline cancer

and screened feline equivalents of approximately:

1,000 human cancer-associated genes.

They identified:

31 cancer driver genes

and found important similarities between the genetic changes driving cancer in cats and humans.

The most striking example was TP53.

It was mutated in:

33% of the cat tumours,

compared with roughly:

34% across a major human pan-cancer analysis.

Feline mammary carcinoma showed particularly interesting parallels with human breast cancer.

More than half of the feline mammary tumours contained alterations in FBXW7, while approximately 47% contained PIK3CA alterations, both genes relevant to human cancer biology.

Researchers also found recurrent feline alterations involving MYC, PTEN and FAS, while uncovering meaningful differences such as the relative absence of RAS driver mutations.

The study does not prove that cats can replace mice, nor does it mean human cancer therapies can immediately be given to feline patients.

What it establishes is something more fundamental:

Cats and humans sometimes reach cancer through remarkably similar genetic routes.

That creates an opportunity.

Pet cats naturally develop tumours.

They age naturally.

They live in human environments.

And their cancers contain molecular changes already familiar to human oncologists.

This makes them promising participants in One Medicine—a research strategy in which discoveries move in both directions between veterinary and human medicine.

A cancer treatment discovered for humans might someday help a cat whose tumour contains the same vulnerable pathway.

A treatment tested ethically in a feline cancer patient might reveal why that pathway responds—or why resistance develops.

That knowledge could then help researchers studying people.

For centuries, cats have shared our homes.

They share our furniture.

Our air.

Some of our environmental exposures.

And now genomics is revealing something much deeper.

When cancer begins inside their cells, it sometimes breaks the same biological machinery that fails inside ours.

The disease crosses species.

Perhaps some of the solutions can too.

Frequently Asked Questions

What did scientists discover about cancer in cats?

Researchers found that many of the genetic mutations driving naturally occurring feline cancers overlap with those found in human cancers.

How many cats were included in the study?

Researchers analyzed tumour and matched healthy tissue from 493 domestic cats.

How many cancer types were studied?

The dataset included 13 different feline cancer types.

How many genes did researchers examine?

They targeted feline equivalents of approximately 1,000 genes already associated with cancer in humans.

Where was the research published?

The study was published in Science under the title The oncogenome of the domestic cat.

When was the study published?

The peer-reviewed study was published on February 19, 2026.

Was the study published by ScienceDaily?

No.

ScienceDaily reported on the research in September 2026. The original peer-reviewed research appeared earlier in Science.

What was the most commonly mutated gene in cat cancer?

TP53 was the most frequently mutated gene.

What percentage of feline tumours had TP53 mutations?

Approximately 33%.

How does that compare with human cancer?

A large human pan-cancer analysis reported TP53 mutations in approximately 34% of tumours.

What does TP53 normally do?

TP53 encodes p53, a tumour-suppressor protein that helps prevent damaged cells from continuing to divide.

Does the matching 33% and 34% mean cat and human cancer are identical?

No.

The similar frequency is striking, but cancer types, biology and genetic landscapes differ between species.

What other important genes were altered in cats?

Researchers identified recurrent alterations involving MYC, PTEN, FAS, FBXW7, PIK3CA and other cancer-associated genes.

How many cancer driver genes did scientists identify?

They identified 31 driver genes across the feline cancers studied.

What is a cancer driver gene?

A driver gene is one whose mutation provides cells with an advantage that contributes directly to tumour development or growth.

Why was feline mammary carcinoma important in the study?

It showed several genetic similarities with human breast cancer, making it particularly interesting for comparative oncology.

What is FBXW7?

FBXW7 helps regulate proteins involved in cell growth. More than half of feline mammary tumours in the study contained alterations affecting it.

What is PIK3CA?

PIK3CA is a cancer-associated gene involved in cellular growth signalling. It was altered in about 47% of the feline mammary carcinomas studied.

Did researchers test cancer drugs on cats?

Not in the relevant mammary-cancer experiment. Researchers tested treatments on feline tumour tissue grown in culture, not in a clinical trial involving living cats.

Could human cancer drugs eventually be used in cats?

Potentially, when a feline tumour contains a suitable molecular target, but drugs would still require veterinary safety, dosage and efficacy studies.

Could studying cats help develop human cancer treatments?

Potentially. Naturally occurring feline cancers may allow researchers to investigate shared mutations, treatment response and resistance in another mammalian species.

Why might cats sometimes be better models than laboratory mice?

Cats naturally develop cancers while aging in ordinary environments shared with humans. This can complement the highly controlled conditions used in laboratory animal models.

Does that mean cats should replace mice in cancer research?

No.

Different models answer different scientific questions. Cats would complement rather than universally replace existing laboratory systems.

What is comparative oncology?

Comparative oncology studies naturally occurring cancers across species to understand shared and different mechanisms of disease.

What is One Medicine?

One Medicine is an approach in which human and veterinary research exchange knowledge so advances in one species can potentially benefit another.

Are cats already used in cancer clinical trials?

Veterinary oncology does conduct clinical research in companion animals, but any trial must have veterinary oversight, ethical safeguards and informed owner consent.

Do cats and humans share environmental cancer risks?

They can share some environmental exposures because pet cats live in human households. Researchers consider this one reason naturally occurring feline cancer may be useful for comparative study.

Does living with a cat mean owners and pets will develop the same cancer?

No.

Shared environment is only one factor among genetics, age, immune biology, random mutation and many other influences.

Were there important differences between cat and human cancers?

Yes. For example, RAS mutations are common drivers in human cancer but did not emerge as drivers among the feline tumour types in this study.

Why are differences between species scientifically useful?

They may reveal why certain cancer pathways matter more in one species and potentially expose protective mechanisms or new therapeutic targets.

Is cancer common in domestic cats?

Cancer is considered an important cause of illness and death in cats, although feline tumour genomics has historically been much less studied than human or canine cancer.

What could happen next?

Researchers can now use the feline cancer atlas to develop molecular diagnostics, identify therapeutic targets and design carefully controlled comparative clinical studies.

The study does not provide a new cure.

It provides something that usually has to come first:

a map.

And that map shows that when cancer evolves inside a cat and when it evolves inside a human, it often follows surprisingly familiar roads.